Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

NCT03023319 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Mesothelioma
Bladder Cancer
Ovarian Cancer
Peritoneal Cancer
Thymoma
Thymus Cancer
Uterine Cervical Cancer

Interventions

DRUG: Bosutinib
DRUG: Pemetrexed

Sponsor

Nagla Abdel Karim